Results from the ATHENA trial, reported in the 12th February issue of the New England Journal of Medicine, suggest that the (as yet unlicensed) antiarrhythmic drug dronedarone can reduce the incidence of cardiovascular-related hospitalisation or death in patients with atrial fibrillation. The study was performed at more than 550 centres in 37 countries.
The ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation have described dronedarone as a derivative of amiodarone (a well established and recommended treatment for atrial fibrillation) under development as an ion-channel blocking drug.
Speaking on behalf of the European Society of Cardiology, Professor Christophe Leclercq from the CHU in Rennes, France, said: “The ATHENA trial shows that dronedarone, a new antiarryhtmic drug similar to amiodarone but with different effects on individual ion channels, reduced the risk of death or hospitalisation for cardiovascular reasons by 36% when compared with placebo. This was in patients without severe heart failure (NYHA class IV) but with paroxysmal or persistent atrial fibrillation or flutter with additional risk factor for death.
“The study found no difference in overall mortality between the two groups but cardiovascular death was significantly reduced with dronedarone by 29%. There was no difference in thyroid-related effects between the two groups. The EURIDIS and ADONIS trials have already shown that dronedarone significantly reduced the recurrence of arrythmias in patients with paroxysmal or persistent atrial fibrillation.
“Dronedarone may thus play a role in the management of atrial arrhythmias in patients with paroxysmal or persistent atrial tachycardias without severe heart failure.”
REFERENCES:1. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
Anne Strauss | alfa
Further reports about: > ACC/AHA/ESC > Experimental antiarrhythmic drug > Placebo > antiarrhythmic drug > atrial fibrillation > cardiovascular risk factor > cardiovascular-related hospitalisation > death rate > derivative of amiodarone > dronedarone > fewer deaths > heart failure > ion-channel blocking drug > paroxysmal > persistent atrial tachycardias > risk factor
Researchers simplify tiny structures' construction drip by drip
12.11.2018 | Princeton University, Engineering School
Mandibular movement monitoring may help improve oral sleep apnea devices
06.11.2018 | Elsevier
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
19.11.2018 | Event News
09.11.2018 | Event News
06.11.2018 | Event News
19.11.2018 | Materials Sciences
19.11.2018 | Information Technology
19.11.2018 | Life Sciences